UniProtKB/Swiss-Prot Q9BXM7: Variant p.Glu417Gly

Serine/threonine-protein kinase PINK1, mitochondrial
Gene: PINK1
Chromosomal location: 1p36
Variant information

Variant position:  417
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Glutamate (E) to Glycine (G) at position 417 (E417G, p.Glu417Gly).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (E) to glycine (G)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Parkinson disease 6 (PARK6) [MIM:605909]: A neurodegenerative disorder characterized by parkinsonian signs such as rigidity, resting tremor and bradykinesia. A subset of patients manifest additional symptoms including hyperreflexia, autonomic instability, dementia and psychiatric disturbances. Symptoms show diurnal fluctuation and can improve after sleep. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In PARK6.
Any additional useful information about the variant.



Sequence information

Variant position:  417
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  581
The length of the canonical sequence.

Location on the sequence:   QLPFSSWYVDRGGNGCLMAP  E VSTARPGPRAVIDYSKADAW
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QLPFSSWYVDRGGNGCLMAPEVSTARPGPRAVIDYSKADAW

Mouse                         RLPFNSSSVERGGNGSLMAPEVSTAHSGPSAVIDYSKADTW

Caenorhabditis elegans        QVDYESDEVSLGGNAKTKAPEIATAVPGKNVKVNFEMADTW

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 78 – 581 Serine/threonine-protein kinase PINK1, mitochondrial
Topological domain 111 – 581 Cytoplasmic
Domain 156 – 511 Protein kinase
Modified residue 402 – 402 Phosphoserine; by autocatalysis


Literature citations

Novel PINK1 mutations in early-onset parkinsonism.
Hatano Y.; Li Y.; Sato K.; Asakawa S.; Yamamura Y.; Tomiyama H.; Yoshino H.; Asahina M.; Kobayashi S.; Hassin-Baer S.; Lu C.-S.; Ng A.R.; Rosales R.L.; Shimizu N.; Toda T.; Mizuno Y.; Hattori N.;
Ann. Neurol. 56:424-427(2004)
Cited for: VARIANTS PARK6 GLN-271; PRO-347 AND GLY-417;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.